Please sign in to follow a disease.
Hydroa vacciniforme-like lymphoma
MONDO:0018224A rare, EBV-positive cutaneous T-cell lymphoproliferative disorder, composed of CD8 positive cytotoxic T-lymphocytes. It affects children, almost exclusively in Latin America and Asia. Patients present with papulovesicular skin lesions, clinically resembling hydroa vacciniforme, in areas of sun-exposed skin.
Also known as: HVLL, angiocentric cutaneous T-cell lymphoma of childhood, hV-like lymphoma, hydroa vacciniforme-like cutaneous T-cell lymphoma, hydroa vacciniforme-like lymphoma, hydroa vacciniforme-like lymphoproliferative disorder, hydroa-like cutaneous T-cell lymphoma
1956 clinical trials for this condition and its sub-types, 3 tagged with Hydroa vacciniforme-like lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare blood cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-stage trial.
Phase 1/2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cell therapy targets EBV-Linked cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the t…
Phase 1/2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC